Research programme: receptor-associated protein therapeutics - Horizon Pharma

Drug Profile

Research programme: receptor-associated protein therapeutics - Horizon Pharma

Alternative Names: AmpTide; HepTide; NeuroTrans; RAP peptide; RAP-2s; RAP-NGF conjugates; Receptor-Associated Protein-Nerve Growth Factor conjugates

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Raptor Pharmaceuticals Corp
  • Developer Horizon Pharma; Raptor Pharmaceutical Corp
  • Class
  • Mechanism of Action Growth factor receptor modulators; Nerve growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C; Liver cancer; Mesothelioma; Neurodegenerative disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in liver cancer in USA (Parenteral)
  • 12 Aug 2014 HepTide™ is still in preclinical development for liver cancer in USA
  • 09 May 2013 No development reported - Preclinical for Neurodegenerative disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top